Skip to content
TrialScanner

NCT05891197

A Biomarker Screening Protocol for Participants With Solid Tumors

No phase registeredTerminatedLYELLeadICLRCollaborator

Registry record

Lead sponsor
Lyell Immunopharma, Inc.
Conditions
Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic; Non-Small Cell Carcinoma of Lung, TNM Stage 4
Primary completion
Feb 5, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05891197 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05891197: A Biomarker Screening... | TrialScanner